FDA approves tildrakizumab for psoriatic arthritisThe FDA cleared Sun Pharma's interleukin-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis in adults, expanding the drug's approved indications.Oct 30, 2026·3 sourcesDrug Policy, Pricing & ApprovalAutoimmune diseaseBiologics license application (BLA)Clinical trialsBiologic therapiesFDA drug approvalAutoimmune disease treatments00
